In this trial, insulin-treated T2D patients were randomized to icodec with an initial 100% loading dose (in which only the first dose was doubled [icodec LD]), icodec with no loading dose (icodec NLD), or glargine U100 for 16 weeks. The gene discussed is INS; the disease is type 2 diabetes mellitus.